Dionysus Healthcare provides myLuma™, a prenatal blood test that measures molecular biomarkers to predict a woman's risk of postpartum depression as early as 28 weeks gestation. The assay delivers a validated risk score to clinicians and patients, enabling targeted preventive care and closer monitoring through existing EHR systems.
Funding
Funding not disclosed
Founders
Product
Problem
Postpartum depression affects a significant portion of new mothers, but current detection relies on delayed self‑reported screening, resulting in many women not receiving timely treatment.
Solution
Dionysus Healthcare offers myLuma™, a prenatal blood assay that quantifies a woman's risk of developing postpartum depression as early as 28 weeks gestation. The test uses molecular biomarkers to generate a clinically validated risk score, which is delivered to both patients and their healthcare providers. By providing actionable risk information well before delivery, clinicians can implement preventive interventions, monitor high‑risk patients more closely, and tailor treatment plans to improve maternal mental health outcomes. The approach shifts maternal care from reactive screening to proactive, precision‑based prevention.
Target Audience
Primary customers are obstetricians, maternal‑fetal medicine specialists, and health systems that provide prenatal and postpartum care.
Features
- Single blood draw performed during routine prenatal visits at ≥28 weeks gestation
- Proprietary molecular biomarker panel that predicts postpartum depression risk with clinically validated accuracy
- Automated risk scoring algorithm delivering a clear, actionable result to clinicians and patients
- Integration-ready reporting format compatible with electronic health record systems
- Supports targeted preventive care pathways, including early counseling and pharmacologic options for high‑risk individuals